BLS Pharmaceuticals Limited (PBIMF) Q4 2026 Earnings Call Transcript

BLS Pharmaceuticals Limited (PBIMF) Q4 2026 Earnings Call September 1, 2026 6:00 PM EDT Company Participants Samuel Watson - CEO, MD & Executive Director Jason Hine - COO & Executive Director Guy Robertson - CFO & Company Secretary Conference Call Participants Melissa Tempra Presentation Melissa Tempra Good morning, everyone, and thank you for joining us for BLS Pharmaceuticals FY '26 Results Webinar. I'm Mel Tempra from NWR Communications and I'll be hosting this morning's session. We will hear from Managing Director and CEO and Founder, Sam Watson; along with Executive Director, Chief Operating Officer, Jason Hine; and Global CFO, Guy Robertson. And with that, I'll hand over to you, Sam. Samuel Watson CEO, MD & Executive Director Thank you very much, Mel. Welcome, everyone, to BLS Pharmaceuticals Full Year Audited Results Presentation for the 2026 financial year, which ended 30th of June. My name is Sam Watson. I'm the CEO and Founder, as Mel mentioned, of BLS. Today, I'm joined by Jason Hine, who's going to take us through some of the operational highlights for the year, and by Guy Robertson, our Chief Financial Officer of the group, and Company Secretary, who is going to provide some commentary on the financials. So FY '26, a year of transformation, scale, international growth. We completed the change of name and our ticker code change to BLS in July, consolidating our shares 10:1. And the purpose of this was to align the corporate identity with the company's operational purpose, vision and its mission. A quick note on the disclaimer. This presentation is not an offer. It's not advice. It may contain forward-looking statements and opinions, which are not to be relied upon. So diving into it, FY '26 is the year that we transformed from an Australian microcap business into a small-cap international pharmaceutical platform. Over